Tumors in Italy: an overview

The data of Istituto Superiore della Sanità indicates that the national average of patients who undergo a colorectal cancer screening is of about 42,6% (60% in the North, 20% in the South).

The data are not surprising: the current and available screening programs for the diagnosis are invasive and expensive exams that discourage the patients.

Source: The European House – Ambrosetti, based on data produced by Istituto Superiore della Sanità, 2019.


Mistral is the best solution for the early diagnosis of the colorectal cancer because it allows the sampling and testing of the patients’ breath on a large scale: it is not invasive, yet rapid, inexpensive and portable.

Mistral is useful for both the patient and the healthcare system because it helps reduce costs and shorten waiting lists.

This site uses cookies to improve the browsing experience of users and to gather information on the use of the site. You can know the details by consulting our cookie policy.